Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc.) on January 11, 2016. The report serves to disclose financial information regarding cash and investment balances as of December 31, 2015, which will be presented to analysts and investors at the J.P. Morgan Healthcare Conference (January 11–14, 2016).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that cash and investment balances as of December 31, 2015, are contained in Exhibit 99.1 (slides #3 and #31 of the corporate presentation), which is incorporated by reference but not detailed within the body of this text.
Material Changes
No material changes versus prior periods are quantified in this filing. The document functions as a notification of upcoming disclosure rather than a report of historical financial performance changes.
Guidance, Outlook, and Risks
- Disclosure Context: The company is utilizing a presentation handout for investor meetings. The handout includes forward-looking statements qualified by cautionary language.
- Legal Status: Information in Items 2.02 and 7.01 is deemed "furnished" and not "filed" under the Securities Exchange Act of 1934. Consequently, it is not subject to Section 18 liabilities and will not be incorporated by reference into future SEC filings.
- Availability: The presentation handout is available on the company's Investor Relations website.
Investor Verification Checklist
- Verify the specific cash and investment balance figures in Exhibit 99.1 (slides #3 and #31), as they are not listed in the main text.
- Review the "cautionary language" slide in Exhibit 99.1 to understand the risks associated with forward-looking statements.
- Confirm the company name is AcelRx Pharmaceuticals, Inc. (Delaware), noting the discrepancy with the metadata request for "TALPHERA, INC."
- Check the company website (www.acelrx.com) for the full presentation handout referenced in Item 7.01.